微小RNA在乳腺癌检测、治疗、耐药及预后中的研究进展

doi:10.3760/cma.j.cn371439-20200306-00115

摘要/Abstract

摘要：

微小RNA(miRNA)在乳腺癌患者中异常表达,可应用于乳腺癌的诊断、治疗、监测等。乳腺癌分子分型不同,临床分期不同,其miRNA表达谱存在显著差异。在乳头溢液、血液、肿瘤组织中进行多种miRNA的联合检测,可综合评估疾病状态,且有助于乳腺癌的早期诊断与治疗。监测治疗后miRNA水平的变化,有助于评估乳腺癌患者治疗效果,监测疾病预后,为疾病复发转移提供及时有效的治疗。靶向调节与耐药相关的miRNA,是乳腺癌治疗新的机遇。

关键词: 微RNAs, 乳腺肿瘤, 早期诊断, 生物学标记, 药理学

Abstract:

microRNAs (miRNAs) are abnormally expressed in patients with breast cancer, which can be used in diagnosis, treatment and monitoring of breast cancer. Different molecular types and clinical stages of breast cancer have significant differences in expression profiles of miRNAs. The combined detection of multiple miRNAs in nipple discharge, blood and tumor tissues can comprehensively evaluate the disease status, which are contribute to the early diagnosis and treatment of breast cancer. Monitoring the level changes of miRNAs after treatment are contribute to assessing the therapeutic effect, monitoring the prognosis of the disease and providing timely and effective treatment for disease recurrence and metastasis. Targeted regulation of miRNAs related to drug resistance is a new opportunity for the treatment of breast cancer.

Key words: microRNAs, Breast neoplasms, Early diagnosis, Biomarkers, pharmacological

刘虹, 吴剑, 李宏江, 羊晓勤. 微小RNA在乳腺癌检测、治疗、耐药及预后中的研究进展[J]. 国际肿瘤学杂志, 2020, 47(12): 756-760.

Liu Hong, Wu Jian, Li Hongjiang, Yang Xiaoqin. Advances of microRNA in the detection, treatment, drug resistance and prognosis of breast cancer[J]. Journal of International Oncology, 2020, 47(12): 756-760.

参考文献 56

[1]	Li T, Mello-Thoms C, Brennan PC. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence[J]. Breast Cancer Res Treat, 2016,159(3):395-406. DOI: 10.1007/s10549-016-3947-0. doi: 10.1007/s10549-016-3947-0 pmid: 27562585
[2]	Hemmatzadeh M, Mohammadi H, Jadidi-Niaragh F, et al. The role of oncomirs in the pathogenesis and treatment of breast cancer[J]. Biomed Pharmacother, 2016,78:129-139. DOI: 10.1016/j.biopha.2016.01.026. doi: 10.1016/j.biopha.2016.01.026 pmid: 26898434
[3]	Asiaf A, Ahmad ST, Arjumand W, et al. MicroRNAs in breast can-cer: diagnostic and therapeutic potential[J]. Methods Mol Biol, 2018,1699:23-43. DOI: 10.1007/978-1-4939-7435-1_2. doi: 10.1007/978-1-4939-7435-1_2 pmid: 29086366
[4]	Ding L, Gu H, Xiong X, et al. MicroRNAs involved in carcinogenesis, prognosis, therapeutic resistance and applications in human triple-negative breast cancer[J]. Cells, 2019,8(12):1492. DOI: 10.3390/cells8121492. doi: 10.3390/cells8121492
[5]	Zhang K, Wang YW, Wang YY, et al. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling[J]. Gene, 2017,619:10-20. DOI: 10.1016/j.gene.2017.03.038. doi: 10.1016/j.gene.2017.03.038 pmid: 28359916
[6]	Tahiri A, Aure MR, Kristensen VN. MicroRNA networks in breast cancer cells[J]. Methods Mol Biol, 2018,1711:55-81. DOI: 10.1007/978-1-4939-7493-1_4. doi: 10.1007/978-1-4939-7493-1_4 pmid: 29344885
[7]	Rohan T, Ye K, Wang Y, et al. MicroRNA expression in benign breast tissue and risk of subsequent invasive breast cancer[J]. PLoS One, 2018,13(2):e0191814. DOI: 10.1371/journal.pone.0191814. doi: 10.1371/journal.pone.0191814 pmid: 29432432
[8]	Prabhu KS, Raza A, Karedath T, et al. Non-coding RNAs as regulators and markers for targeting of breast cancer and cancer stem cells[J]. Cancers (Basel), 2020,12(2):351. DOI: 10.3390/cancers12020351. doi: 10.3390/cancers12020351
[9]	Moi L, Braaten T, AI-Shibli K, et al. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study[J]. J Transl Med, 2019,17(1):334. DOI: 10.1186/s12967-019-2086-x. doi: 10.1186/s12967-019-2086-x pmid: 31581940
[10]	Xiao S, Zhu H, Luo J, et al. miR 425 5p is associated with poor prognosis in patients with breast cancer and promotes cancer cell progression by targeting PTEN[J]. Oncol Rep, 2019,42(6):2550-2560. DOI: 10.3892/or.2019.7371. doi: 10.3892/or.2019.7371 pmid: 31638259
[11]	Han JG, Jiang YD, Zhang CH, et al. A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer[J]. Ann Surg Treat Res, 2017,92(2):55-66. DOI: 10.4174/astr.2017.92.2.55. doi: 10.4174/astr.2017.92.2.55 pmid: 28203552
[12]	Cava C, Novello C, Martelli C, et al. Theranostic application of miR-429 in HER2⁺ breast cancer[J]. Theranostics, 2020,10(1):50-61. DOI: 10.7150/thno.36274. doi: 10.7150/thno.36274 pmid: 31903105
[13]	Grimaldi AM, Incoronato M. Clinical translatability of "identified" circulating miRNAs for diagnosing breast cancer: overview and update[J]. Cancers (Basel), 2019,11(7):901. DOI: 10.3390/cancers11070901. doi: 10.3390/cancers11070901
[14]	Rizzo FM, Meyer T. Liquid biopsies for neuroendocrine tumors: circulating tumor cells, DNA, and microRNAs[J]. Endocrinol Metab Clin North Am, 2018,47(3):471-483. DOI: 10.1016/j.ecl.2018.04.002. doi: 10.1016/j.ecl.2018.04.002 pmid: 30098711
[15]	Armand-Labit V, Pradines A. Circulating cell-free microRNAs as clinical cancer biomarkers[J]. Biomol Concepts, 2017,8(2):61-81. DOI: 10.1515/bmc-2017-0002. doi: 10.1515/bmc-2017-0002 pmid: 28448269
[16]	Fehlmann T, Ludwig N, Backes C, et al. Distribution of microRNA biomarker candidates in solid tissues and body fluids[J]. RNA Biol, 2016,13(11):1084-1088. DOI: 10.1080/15476286.2016.1234658. doi: 10.1080/15476286.2016.1234658 pmid: 27687236
[17]	Loke SY, Munusamy P, Koh GL, et al. A circulating miRNA signature for stratification of breast lesions among women with abnormal screening mammograms[J]. Cancers (Basel), 2019,11(12):1872. DOI: 10.3390/cancers11121872. doi: 10.3390/cancers11121872
[18]	McAnena P, Tanriverdi K, Curran C, et al. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer[J]. BMC Cancer, 2019,19(1):436. DOI: 10.1186/s12885-019-5636-y. doi: 10.1186/s12885-019-5636-y pmid: 31077182
[19]	Best MG, Sol N, Kooi I, et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics[J]. Cancer Cell, 2015,28(5):666-676. DOI: 10.1016/j.ccell.2015.09.018. doi: 10.1016/j.ccell.2015.09.018 pmid: 26525104
[20]	Zhang K, Zhao S, Wang Q, et al. Identification of microRNAs in nipple discharge as potential diagnostic biomarkers for breast cancer[J]. Ann Surg Oncol, 2015,22 Suppl 3: S536-S544. DOI: 10.1245/s10434-015-4586-0.
[21]	Do Canto LM, Marian C, Willey S, et al. MicroRNA analysis of breast ductal fluid in breast cancer patients[J]. Int J Oncol, 2016,48(5):2071-2078. DOI: 10.3892/ijo.2016.3435. doi: 10.3892/ijo.2016.3435 pmid: 26984519
[22]	Gomes BC, Santos B, Rueff J, et al. Methods for studying micro-RNA expression and their targets in formalin-fixed, paraffin-embedded (FFPE) breast cancer tissues[J]. Methods Mol Biol, 2016,1395:189-205. DOI: 10.1007/978-1-4939-3347-1_11. doi: 10.1007/978-1-4939-3347-1_11 pmid: 26910075
[23]	Pardini B, Sabo AA, Birolo G, et al. Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies[J]. Cancers (Basel), 2019,11(8):1170. DOI: 10.3390/cancers11081170. doi: 10.3390/cancers11081170
[24]	Jayaraj R, Nayagam SG, Kar A, et al. Clinical theragnostic relationship between drug-resistance specific miRNA expressions, chemotherapeutic resistance, and sensitivity in breast cancer: a systematic review and meta-analysis[J]. Cells, 2019,8(10):1250. DOI: 10.3390/cells8101250. doi: 10.3390/cells8101250
[25]	Chen J, Tian W, He H, et al. Downregulation of miR 200c 3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2[J]. Oncol Rep, 2018,40(6):3821-3829. DOI: 10.3892/or.2018.6735. doi: 10.3892/or.2018.6735 pmid: 30272330
[26]	Guan X, Gu S, Yuan M, et al. MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition[J]. Oncol Lett, 2019,18(6):5986-5994. DOI: 10.3892/ol.2019.10984. doi: 10.3892/ol.2019.10984 pmid: 31788073
[27]	Wang G, Dong Y, Liu H, et al. Loss of miR-873 contributes to gemcitabine resistance in triple-negative breast cancer via targeting ZEB1[J]. Oncol Lett, 2019,18(4):3837-3844. DOI: 10.3892/ol.2019.10697. doi: 10.3892/ol.2019.10697 pmid: 31579087
[28]	Duan WJ, Bi PD, Ma Y, et al. MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer cells via targeting Livin[J]. Neoplasma. 2020,67(1):102-110. DOI: 10.4149/neo_2019_190106N18. doi: 10.4149/neo_2019_190106N18 pmid: 31777256
[29]	Medarova Z, Pantazopoulos P, Yoo B. Screening of potential miRNA therapeutics for the prevention of multi-drug resistance in cancer cells[J]. Sci Rep, 2020,10(1):1970. DOI: 10.1038/s41598-020-58919-2. doi: 10.1038/s41598-020-58919-2 pmid: 32029822
[30]	Ueda S, Takanashi M, Sudo K, et al. miR-27a ameliorates chemoresistance of breast cancer cells by disruption of reactive oxygen species homeostasis and impairment of autophagy[J]. Lab Invest, 2020,100(6):863-873. DOI: 10.1038/s41374-020-0409-4. doi: 10.1038/s41374-020-0409-4 pmid: 32066826
[31]	Li F, Miao L, Xue T, et al. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells[J]. J Exp Clin Cancer Res, 2019,38(1):414. DOI: 10.1186/s13046-019-1404-8. doi: 10.1186/s13046-019-1404-8 pmid: 31601253
[32]	Hou L, Zhao Y, Song GQ, et al. Interfering cellular lactate homeostasis overcomes Taxol resistance of breast cancer cells through the microRNA-124-mediated lactate transporter (MCT1) inhibition[J]. Cancer Cell Int, 2019,19:193. DOI: 10.1186/s12935-019-0904-0. doi: 10.1186/s12935-019-0904-0 pmid: 31367191
[33]	Zhao C, Ling X, Li X, et al. MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1[J]. Breast Cancer, 2019,26(6):817-825. DOI: 10.1007/s12282-019-00989-w. doi: 10.1007/s12282-019-00989-w pmid: 31243644
[34]	Ruan L, Qian X. MiR-16-5p inhibits breast cancer by reducing AKT3 to restrain NF-κB pathway[J]. Biosci Rep, 2019,39(8): BSR20191611. DOI: 10.1042/BSR20191611. doi: 10.1042/BSR20190720 pmid: 31366565
[35]	Sereno M, Haskó J, Molnár K, et al. Downregulation of circulating miR 802-5p and miR 194-5p and upregulation of brain MEF2C along breast cancer brain metastasization[J]. Mol Oncol, 2020,14(3):520-538. DOI: 10.1002/1878-0261.12632. doi: 10.1002/1878-0261.12632 pmid: 31930767
[36]	Wang Z, Li TE, Chen M, et al. miR-106b-5p contributes to the lung metastasis of breast cancer via targeting CNN1 and regulating Rho/ROCK1 pathway[J]. Aging (Albany NY), 2020,12(2):1867-1887. DOI: 10.18632/aging.102719.
[37]	Martinez-Gutierrez AD, Catalan OM, Vázquez-Romo R, et al. miRNA profile obtained by next generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments[J]. Int J Mol Med, 2019,44(4):1267-1280. DOI: 10.3892/ijmm.2019.4292 doi: 10.3892/ijmm.2019.4292 pmid: 31364724
[38]	Estevão-Pereira H, Lobo J, Salta S, et al. Overexpression of circulating miR-30b-5p identifies advanced breast cancer[J]. J Transl Med, 2019,17(1):435. DOI: 10.1186/s12967-019-02193-y. doi: 10.1186/s12967-019-02193-y pmid: 31888645
[39]	Lasham A, Fitzgerald SJ, Knowlton N, et al. A predictor of early disease recurrence in patients with breast cancer using a cell-free RNA and protein liquid biopsy[J]. Clin Breast Cancer, 2020,20(2):108-116. DOI: 10.1016/j.clbc.2019.07.003. doi: 10.1016/j.clbc.2019.07.003 pmid: 31607655
[40]	Ozawa PMM, Vieira E, Lemos DS, et al. Identification of miRNAs enriched in extracellular vesicles derived from serum samples of breast cancer patients[J]. Biomolecules, 2020,10(1):150. DOI: 10.3390/biom10010150. doi: 10.3390/biom10010150
[41]	Rohan TE, Wang T, Weinmann S, et al. A miRNA expression signature in breast tumor tissue is associated with risk of distant metastasis[J]. Cancer Res, 2019,79(7):1705-1713. DOI: 10.1158/0008-5472.CAN-18-2779. doi: 10.1158/0008-5472.CAN-18-2779 pmid: 30760517
[42]	Lai J, Chen B, Zhang G, et al. Identification of a novel microRNA recurrence-related signature and risk stratification system in breast cancer[J]. Aging (Albany NY), 2019,11(18):7525-7536. DOI: 10.18632/aging.102268.
[43]	Amorim M, Lobo J, Fontes-Sousa M, et al. Predictive and prognostic value of selected microRNAs in luminal breast cancer[J]. Front Genet, 2019,10:815. DOI: 10.3389/fgene.2019.00815. doi: 10.3389/fgene.2019.00815 pmid: 31572437
[44]	Kanchan RK, Siddiqui JA, Mahapatra S, et al. microRNAs orchestrate pathophysiology of breast cancer brain metastasis: advances in therapy[J]. Mol Cancer, 2020,19(1):29. DOI: 10.1186/s12943-020-1140-x. doi: 10.1186/s12943-020-1140-x pmid: 32059676
[45]	Michael IP, Saghafinia S, Hanahan D. A set of microRNAs coordinately controls tumorigenesis, invasion, and metastasis[J]. Proc Natl Acad Sci U S A, 2019,116(48):24184-24195. DOI: 10.1073/pnas.1913307116. doi: 10.1073/pnas.1913307116 pmid: 31704767
[46]	Hoseinbeyki M, Taha MF, Javeri A. miR-16 enhances miR-302/367-induced reprogramming and tumor suppression in breast cancer cells[J]. IUBMB Life, 2020,72(5):1075-1086. DOI: 10.1002/iub.2249. doi: 10.1002/iub.2249 pmid: 32057163
[47]	Alizadeh S, Isanejad A, Sadighi S, et al. Effect of a high-intensity interval training on serum microRNA levels in women with breast cancer undergoing hormone therapy. A single-blind randomized trial[J]. Ann Phys Rehabil Med, 2019,62(5):329-335. DOI: 10.1016/j.rehab.2019.07.001. doi: 10.1016/j.rehab.2019.07.001 pmid: 31400480
[48]	Sun WM, Tao W, Li JC, et al. MicroRNA-296 functions as a tumor suppressor in breast cancer by targeting FGFR1 and regulating the Wnt/β-catenin signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2019,23(23):10422-10432. DOI: 10.26355/eurrev_201912_19681. doi: 10.26355/eurrev_201912_19681 pmid: 31841196
[49]	Ansari MA, Thiruvengadam M, Farooqui Z, et al. Nanotechnology,insilico and endocrine-based strategy for delivering paclitaxel and miRNA: prospects for the therapeutic management of breast cancer[J]. Semin Cancer Biol, 2019,S1044-579X(19) 30422-5. DOI: 10.1016/j.semcancer.2019.12.022.
[50]	Umeh-Garcia M, Simion C, Ho PY, et al. A novel bioengineered miR-127 prodrug suppresses the growth and metastatic potential of triple-negative breast cancer cells[J]. Cancer Res, 2020,80(3):418-429. DOI: 10.1158/0008-5472.CAN-19-0656. doi: 10.1158/0008-5472.CAN-19-0656 pmid: 31694904
[51]	Das PK, Siddika MA, Asha SY, et al. MicroRNAs, a promising target for breast cancer stem cells[J]. Mol Diagn Ther, 2020,24(1):69-83. DOI: 10.1007/s40291-019-00439-5. doi: 10.1007/s40291-019-00439-5 pmid: 31758333
[52]	Zou Y, Lin X, Bu J, et al. Timeless-stimulated miR-5188-FOXO1/β-Catenin-c-Jun feedback loop promotes stemness via ubiquitination of β-Catenin in breast cancer[J]. Mol Ther, 2020,28(1):313-327. DOI: 10.1016/j.ymthe.2019.08.015. doi: 10.1016/j.ymthe.2019.08.015 pmid: 31604679
[53]	Grinán-Lisón C, Olivares-Urbano MA, Jiménez G, et al. miRNAs as radio-response biomarkers for breast cancer stem cells[J]. Mol Oncol, 2020,14(3):556-570. DOI: 10.1002/1878-0261.12635. doi: 10.1002/1878-0261.12635 pmid: 31930680
[54]	Taslim C, Weng DY, Brasky TM, et al. Discovery and replication of microRNAs for breast cancer risk using genome-wide profiling[J]. Oncotarget, 2016,7(52):86457-86468. DOI: 10.18632/oncotarget.13241. doi: 10.18632/oncotarget.13241 pmid: 27833082
[55]	Izzotti A, Carozzo S, Pulliero A, et al. Extracellular microRNA in liquid biopsy: applicability in cancer diagnosis and prevention[J]. Am J Cancer Res, 2016,6(7):1461-1493. pmid: 27508091
[56]	Akbulut H, Ersoy YE, Coskunpinar E, et al. The role of miRNAs as a predictor of multicentricity in breast cancer[J]. Mol Biol Rep, 2019,46(2):1787-1796. DOI: 10.1007/s11033-019-04629-6. doi: 10.1007/s11033-019-04629-6 pmid: 30707415